Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | EYA2 | O00167 | 1/20 | 0.44 |
| ▸ | APP | P05067 | 1/20 | 0.44 |
| ▸ | ACE | P12821 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 4/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.42 |
| ▸ | DRD1 | P21728 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12673457 | 0.83 | TDP1 (0.42) | TDP1EYA2APPACEBLM | |
| SCHEMBL19067310 | 0.83 | TDP1 (0.45) | TDP1EYA2APPACEBLM | |
| SCHEMBL6152638 | 0.81 | TDP1 (0.40) | TDP1EYA2APPACEBLM | |
| SCHEMBL9626421 | 0.80 | TDP1 (0.50) | TDP1EYA2APPACEBLM | |
| SCHEMBL21096057 | 0.79 | TDP1 (0.48) | TDP1EYA2APPACEBLM | |
| SCHEMBL20000671 | 0.79 | TDP1 (0.48) | TDP1EYA2APPACEBLM | |
| SCHEMBL12296559 | 0.78 | GSR (0.42) | BLMLMNAALOX15SLC6A2SLC6A3 | |
| SCHEMBL15834505 | 0.78 | TDP1 (0.44) | TDP1EYA2APPACEBLM | |
| SCHEMBL21320313 | 0.78 | TDP1 (0.44) | TDP1EYA2APPACEBLM | |
| SCHEMBL12650723 | 0.78 | TDP1 (0.44) | TDP1EYA2APPACEBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0948361-B1 | MAGNETIC RESONANCE BLOOD POOL AGENTS | MALLINCKRODT INC (US) | 2005-01-26 | — | — | EP | claimed |
| EP-0948361-A4 | MAGNETIC RESONANCE BLOOD POOL AGENTS | MALLINCKRODT MEDICAL INC (US) | 2001-02-07 | — | — | EP | claimed |
| EP-0948361-A1 | MAGNETIC RESONANCE BLOOD POOL AGENTS | MALLINCKRODT MEDICAL, INC. (US) | 1999-10-13 | — | — | EP | claimed |
| US-5961953-A | CONTAINING BICYCLO(2.2.2)OCTANE, ADAMANTANE, OR DICYCLOHEXYLACETYL GROUPS AND CHELATING GROUPS | MALLINCKRODT INC. (US) | 1999-10-05 | — | — | US | claimed |
| US-5888476-A | ADMINISTERING A GADOLINIUM COMPLEX AS A CONTRAST AGENT FOR MAGNETIC RESONANCE IMAGING WHICH INCREASE RELAXIVITY OF WATER PROTONS SURROUNDING THE TISSUE | MALLINCKRODT MEDICAL, INC. (US) | 1999-03-30 | — | — | US | claimed |
| WO-1998020908-A1 | MAGNETIC RESONANCE BLOOD POOL AGENTS | MALLINCKRODT MEDICAL, INC. (US) | 1998-05-22 | — | — | WO | claimed |
| WO-2021202830-A2 | HSP90-BINDING CONJUGATES AND FORMULATIONS THEREOF | TARVEDA THERAPEUTICS, INC. (US) | 2021-10-07 | — | — | WO | disclosed |
| WO-2020205948-A1 | HSP90-BINDING CONJUGATES AND FORMULATIONS THEREOF | TARVEDA THERAPEUTICS, INC. (US) | 2020-10-08 | — | — | WO | disclosed |
| WO-2019195384-A1 | HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF | TARVEDA THERAPEUTICS, INC. (US) | 2019-10-10 | — | — | WO | disclosed |
| US-9764048-B2 | Targeted molecular imaging probe and method for in vivo molecular imaging | SHEN BAOZHONG (CN) | 2017-09-19 | — | — | US | disclosed |
| US-9764048-B2 | Targeted molecular imaging probe and method for in vivo molecular imaging | SHEN BAOZHONG (CN) | 2017-09-19 | — | — | US | disclosed |
| US-20150202335-A1 | TARGETED MOLECULAR IMAGING PROBE AND METHOD FOR IN VIVO MOLECULAR IMAGING | SHEN BAOZHONG (CN) | 2015-07-23 | — | — | US | disclosed |
| US-20150202335-A1 | TARGETED MOLECULAR IMAGING PROBE AND METHOD FOR IN VIVO MOLECULAR IMAGING | SHEN BAOZHONG (CN) | 2015-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150202335-A1 | TARGETED MOLECULAR IMAGING PROBE AND METHOD FOR IN VIVO MOLECULAR IMAGING | GJB2, GJA1, GAP43 | TDP1 2268/4885EYA2 3986/4885APP 1242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.